France · Delayed Price · Currency is EUR Clariane SE Earnings Call Transcripts
Fiscal Year 2026
-
Solid organic revenue growth of +4.9% in Q1 2026 was driven by improved occupancy, pricing, and strong performance across all segments and geographies. Liquidity was strengthened by a successful EUR 500 million bond issue, and medium-term guidance was confirmed.
Fiscal Year 2025
-
Delivered strong 2025 results with 4.5% organic revenue growth, improved profitability, and reduced leverage. Strategic divestments, cost efficiency programs, and a robust outlook support continued margin and cash flow gains through 2028.
-
Q3 2025 saw accelerated organic revenue growth (+5.1%) and strong segment performance, with all geographies contributing. Financial structure was reinforced through early asset disposals and a €500M bond, while cost reduction measures ramp up more slowly, supporting margin improvement into 2026.
-
Solid H1 2025 results with 4.8% organic revenue growth, successful €1B asset disposal, and strengthened liquidity. Guidance for 6–9% EBITDA growth and leverage below 5.5x is confirmed, with margin recovery expected in H2 from pricing and operational improvements.
-
The meeting confirmed strong financial recovery, with sales up 6.6% and net profit returning to positive. Major governance changes included a new Chair and updated remuneration policies. All resolutions passed, and the group continues to focus on debt reduction, asset divestment, and climate adaptation.
-
Q1 2025 organic revenue grew 4.8% (5.5% ex-leap year), with all segments and regions contributing. Asset disposals reached €600 million, targeting €1 billion by end-2025, and 2025 guidance for revenue and EBITDA growth is confirmed. HoldCo leverage is set to fall below 5.5x.
Fiscal Year 2024
-
Solid organic revenue growth of 6.6% and improved operating margin marked a recovery year, with €409 million debt reduction and 50% of the €1 billion asset disposal plan completed. 2025 guidance targets 5% sales growth, 6–9% EBITDA growth, and further deleveraging.
-
Organic revenue grew 6.3% in the first nine months of 2024, driven by both price and volume, with all segments and regions contributing. Asset disposals progressed, supporting liquidity for upcoming maturities, and 2024 guidance for >5% organic growth and stable EBITDA was reaffirmed.
-
Revenue grew 6.8% organically in H1 2024, with EBITDA and cash flow improving and net debt reduced by EUR 500 million. Asset disposals and refinancing progressed, outlook reaffirmed, and new build program scaled back to 2,700 pre-financed beds.